drugset
drugset / Trial / NCT03981536

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

NCT03981536 ↗

Phase 1 Unknown 18 enrolled AL-S Pharma
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Single ascending doses of AP-101 will be administered by intravenous (IV) infusion

Timeline

Start
2019-10-10
Primary completion
2020-11-02
Completion
2020-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AP-101 Unknown — Intravenous

Indications

amyotrophic lateral sclerosis